Key facts
- Gen House’s last known valuation is $268.3M (Jan 2026).
- It has raised $120.5M; the latest was IPO in Jan 2026.
- Notable investors include Shenzhen Capital Group, Green Pine Capital Partners, Legend Star, YuanBio Venture Capital, DPH Capital — 23 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Gen House
- ·The full record, as it builds
Funding rounds
No funding rounds for Gen House are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gen House
Developer of original anti-tumor drugs designed for anti-cancer therapeutics. The company develops new tumor immunotherapy drugs and clinical detection methods based on precision medicine, enabling patients to have better treatment through the combined drug delivery of large molecules and small molecules.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2014
- Employees
- 31
- Website
- genhousebio.com/
- Ownership
- In IPO Registration
Gen House doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gen House shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gen House in its N-PORT filings yet. We sweep new filings monthly.